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Abstract
Background: Cardiovascular development is vital for embryonic survival and growth. Early gestation embryo loss or
malformation has been linked to yolk sac vasculopathy and congenital heart defects (CHDs). However, the molecular
pathways that underlie these structural defects in humans remain largely unknown hindering the development of
molecular-based diagnostic tools and novel therapies.
Methodology/Principal Findings: Murine embryos were exposed to high glucose, a condition known to induce
cardiovascular defects in both animal models and humans. We further employed a mass spectrometry-based proteomics
approach to identify proteins differentially expressed in embryos with defects from those with normal cardiovascular
development. The proteins detected by mass spectrometry (WNT16, ST14, Pcsk1, Jumonji, Morca2a, TRPC5, and others)
were validated by Western blotting and immunoflorescent staining of the yolk sac and heart. The proteins within the
proteomic dataset clustered to adhesion/migration, differentiation, transport, and insulin signaling pathways. A functional
role for several proteins (WNT16, ADAM15 and NOGO-A/B) was demonstrated in an ex vivo model of heart development.
Additionally, a successful application of a cluster of protein biomarkers (WNT16, ST14 and Pcsk1) as a prenatal screen for
CHDs was confirmed in a study of human amniotic fluid (AF) samples from women carrying normal fetuses and those with
CHDs.
Conclusions/Significance: The novel finding that WNT16, ST14 and Pcsk1 protein levels increase in fetuses with CHDs
suggests that these proteins may play a role in the etiology of human CHDs. The information gained through this bed-side
to bench translational approach contributes to a more complete understanding of the protein pathways dysregulated
during cardiovascular development and provides novel avenues for diagnostic and therapeutic interventions, beneficial to
fetuses at risk for CHDs.
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Introduction
The foundations of the primitive heart form between gastrulation
and early organogenesis, as critical specification, differentiation, and
morphogenic events occur. During this period, the embryo is highly
susceptible to environmental insults and genetic lesions that perturb
cardiovascular development. These disturbances lead to congenital
heart defects (CHDs), a significant cause of spontaneous abortions
(20%) and infant mortality (10% of all infant deaths) [1]. Of live
births, approximately 1% experience a spectrum of CHDs including
transposition of the great arteries, double outlet right ventricle,
tetralogy of Fallot, and septal defects [2]. The majority of cardiac
malformations (30%) are ventricular septal defects, an abnormal
communication between the left and right ventricles [3]. These
cardiac anomalies, and several others, arise in part due to
morphogenesis defects in the primitive valve tissues (endocardial
cushions) which reside in the atrioventricular canal and outflow tract
[4]. Within these specific regions of the primitive heart, endothelial
cells undergo a key differentiation event, epithelial to mesenchymal
transition (EMT) [4]. Lineage tracing experiments and serial
anatomical dissection/reconstruction have demonstrated that these
mesenchymal cells contribute to the mature mitral and tricuspid
valve leaflets as well as the interatrial and interventricular septa
[5,6,7,8,9]. Therefore miscues in the endocardial cushion early in
development would affect the ultimate formation of these and other
cardiac structures later in development.
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on imaging the visible structural defect. Indications for fetal
echocardiography include risk factors based on family history,
exposures, or other fetal findings [10,11,12]. At this point, however,
the structural defect has developed and in the current standard of
care the clinical intervention is postnatal surgery. Approaching the
diagnosis problem from a bed-side-to-bench manner, we believe a
molecular-based detection method has the potential to revolutionize
the diagnosis and treatment of cardiovascular defects. Therefore a
studywasdesignedinwhichbiomarkerdiscoverywasperformedina
controlled murine model, and then validated for biological
significance in human amniotic fluid (AF). A biomarker approach
utilizing biochemical analyses of maternal or fetal fluids would
provide clinicians with information regarding the pathophysiological
condition of the fetus and potentially identify biological deficiencies
in the fetal environment. Thus, molecular-based detection provides
additional information to guide clinical interventions and may pave
the way for the development of novel treatments based on dietary
supplementation [13].
The development of such interventions has been hindered by
our incomplete knowledge of human cardiac development. A
number of genes that drive cardiovascular development have been
described in mouse, zebrafish, and chicken model systems,
although only a handful of genes such as PTPN11, TBX5
GATA4, and Nkx2.5 have been definitively identified in the
etiology of human CHDs [4]. Furthermore, little is known about
defects at the protein level. Thus this project aimed to identify
novel proteins involved in both cardiovascular development and
CHDs.
Identification of proteins involved in specific cardiac develop-
mental events using whole embryonic hearts is difficult because it
requires distinguishing and deconvoluting candidate proteins
expressed concurrently during endocardial cushion morphogene-
sis, cardiomyocyte differentiation, looping and/or chamber
specification. Therefore, our strategy utilized yolk sac vascular
tissue rather than cardiac tissue for proteomic studies. Our
hypothesis was that proteins involved in cardiac development and
CHDs could be isolated and characterized from the vascular tissue
dataset for the following reasons. Yolk sac tissue at the primary
capillary plexus stage provides a relatively simple, homogeneous
tissue consisting of few cell types in which the primary
developmental event is endothelial differentiation and assembly
into a mature vascular bed. In the heart, endothelial cell
differentiation via EMT is a key event in endocardial cushion
morphogenesis. Additionally, trabeculation and coronary system
development both also rely on endothelial transdifferentiation or
endothelial cell reorganization and assembly. Thus, during
development of both the yolk sac and heart, endothelial biology
plays a central role. The overlapping developmental pathways in
the vasculature and heart have been revealed by the generation of
numerous knockout mice that have described both vascular and
cardiac phenotypes. This pattern may be a reflection of a common
endothelial/cardiac progenitor (though a controversial theory),
non-cell autonomous interactions between endothelial and cardiac
progenitor lines which are intermingling during migration through
the splanchnic mesoderm, or the intimate juxtaposition of
differentiated endothelial cells and cardiomyocytes in the embry-
onic heart [14,15,16,17,18]. Thus although there is heterogeneity
in the type of heart defects that present in the humans there will be
a set of markers which will be inherently common to all heart
defects because endothelial cell differentiation is a key process in
heart development.
From our vascular proteomic dataset, we assembled a list of
differentially expressed proteins which were validated by Western
blot. The data accrued through these studies highlight the
importance of adhesion/migration, differentiation, transport, and
insulin/insulin like growth factor (IGF) pathways in cardiovascular
development. Immunofluorescence microscopy studies demon-
strated the presence of many of these proteins (including Morca2a,
TRPC5, Enolase 1, Fbxo42, ST14, and Jumonji) in the embryonic
heart. Subsequent functional analysis in an ex vivo cardiac culture
model revealed novel roles for Collagen IV, NOGO-A/B,
WNT16 and ADAM15 in heart development. Together with the
immunofluorescence data, the functional analysis data confirmed
that our approach did identify proteins relevant to cardiac
development. In our dataset, molecules that may be useful as
biomarkers in human AF were targeted, in particular secreted
proteins and protein ectodomains. The successful application of a
cluster of proteins (WNT16, ST14 and Pcsk1) as biomarkers of
CHDs was confirmed in a study of human AF samples from
women carrying normal fetuses and those with CHDs. This study
adds new information to our understanding of the molecular
pathways underlying normal and abnormal cardiovascular
development, paving the way for the development of novel
prenatal screens and treatments for human fetuses with CHDs.
Materials and Methods
Mice
CD1 mice (Charles River) were maintained under standard
conditions. Timed-matings were detected by the presence of a
vaginal plug. NOGO-A/B mice were provided by Steve
Strittmatter (Yale University). The Yale University Animal Care
and Use Committee approved all animal protocols and experi-
mentation was performed in accordance with National Institute of
Health regulations.
Whole Embryo Culture
Conceptuses were harvested at 7.5 dpc and cultured for
48 hours in pooled rat serum supplemented with 20 mm of the
nitric oxide donor NOC-18 (2,29-(hydroxynitrosohydrazino)bis-
ethanamine) (Calbiochem), 10 pg/ml rVEGF (Chemicon),
20 mM L-glucose (control) and/or 20 mM D-glucose. The
developmental stage was determined using Downs and Davies’
criteria for staging morphological landmarks of the primitive
streak, neural plate and head fold [19]. Embryos from head fold
stage to somite stage 27–30 correspond to human gestational
weeks 3–6 [20,21,22]. Embryos were examined under a dissecting
microscope for gross defects (neural tube closure, axial rotation
completion, yolk sac circulation and heart beat) and processed for
mass spectrometry.
Atrioventricular Canal Explant Assay
Atrioventricular canals were isolated from E9.0 embryos and
placed onto a 1 mg/ml Type I Rat Tail collagen gel (BD
Biosciences). The explants were allowed to adhere prior to the
addition of media [Medium 199, 1% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin, and 0.1% each of insulin, transferrin,
and selenium (GIBCO)] [23]. Cultures were stopped at 48–
72 hours, fixed with 4% paraformaldehyde and stained with F-
actin (Invitrogen) to evaluate cellular morphology. All experiments
were repeated at least five times.
Liquid Chromatography Tandem Mass Spectrometry
Individual 8.5 dpc yolk sacs were lysed in RapiGest SF (Waters),
digested with trypsin (Princeton Separations), and desalted using
C-18 columns (VivaScience). LC-MS and LC-MS-MS analysis
were performed on a Q-TOF API-US quadrupole time of flight
Cardiovascular Protein Cluster
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electrospray and nonospray sources. Peptides were eluted into the
source following chromatography on a capillary HPLC CapLC
system equipped with a dual wave length UV detector (Waters).
For both standard ESI (flow set at 10 uL/min) and nonoflow (flow
set at 100 nL/min) ionization methods a linear 30 min gradient of
increasing acetonitrile concentration was applied to fractionate
and elute the samples. The mass spectrometer’s source voltage for
this application was set at 3.5 kV with scan time duration of 1 s/
scan and spectra were acquired using both survey and parent scan
MS methods with data dependent acquisition (DDA) setting
defined by MassLynx software instrument interface. Following
acquisition, data was preprocessed automatically by MassLynx
and the resulting MS-MS spectra was submitted to MZmine for
post-acquisition processing (peak picking, data alignment, and
normalization) to generate the peak intensity matrix [24,25]. Data
analysis was performed with Matlab and Excel. First the intensity
matrix was filtered by dropping away peaks which were detected
in less than 5 samples. This left 12908 rows to intensity matrix. T-
test (unpaired; two-tailed; equal variances) and log ratio values
were calculated for each peak between sample and control
independently for all three sample/control pairs: HG vs. control,
HG+rVEGF vs. control, and HG+nitric oxide donor vs. control.
Log ratios were calculated as average peak intensity in the sample
divided by average peak intensity in the control (Table S1). To find
peaks with differential intensity between sample and control,
threshold levels p-value,0.05 and absolute (log ratio)$1 were
used in each pair. These peaks were targeted (in an aliquot of the
original yolk sac lysate sample) for MS-MS fragmentation and
their spectra were searched against the nonredundant protein
sequence database (NCBI, National Center for Biotechnology)
using the Mascot search engine.
Immunofluorescence
Conceptuses were harvested from timed-pregnant mice at the
indicated time points, frozen in OCT medium and cryo-sectioned
(10 mm). Immunoreactivity was visualized with Alexa Fluor 594 or
488 secondary antibodies (Invitrogen). Nuclei were stained with
DAPI. Digital images were captured on an Olympus IX71
Inverted Microscope.
Western Blot
Yolk sacs were harvested from culture conditions at the
indicated time points and lysed in RIPA Buffer (Upstate)
supplemented with 1% SDS, Complete Protease Inhibitor
Cocktail (Roche) and Phosphatase Inhibitor Cocktails (Calbio-
chem). The samples were homogenized and soluble extracts
obtained by centrifugation. Protein concentrations were deter-
mined by BCA Assay (Bio-Rad) and 25 mg was electrophoresed on
SDS-PAGE gels (Bio-Rad). Luminescence was performed using
the Western Lightening Chemiluminescence Reagent (PerkinEl-
mer) and densitometry using Quantity One Software (Bio-Rad).
Antibodies
Primary antibodies included NOGO-A (gift from Steve
Strittmatter, Yale), PECAM (J.A.M), Laminin 1 (J.A.M.), a
smooth muscle cell actin (Sigma), ADAM15 ectodomain (R&D
Systems), WNT16 (BD Pharmigen), SCVT (Slc23a1) (Alpha
Diagnostic International), Collagen IV (Abcam and USBiological),
PIASc (Abcam), TRPC5 (Chemicon), KIF21B (Upstate), Erk2
(Santa Cruz), NOGO-A/B (Santa Cruz), Enolase 1 (USBiologi-
cal), and the following from Novus: Fbxo42, Jumonji, Pcsk1,
ST14, CHST3 and ZCWCC1 (Morca2a).
Zymography
Yolk sacs were lysed in 50 mM Tris/1% Triton-X and
homogenized with a motorized pestle. 25 mg of protein was mixed
with non-reducing Laemmli buffer and loaded onto a 10%
Zymogram Gel (Bio-Rad) for electrophoresis. The gels were
washed in 2.5% Triton X-100, followed by water, and incubated
for 48–72 h at 37uC in a 50 mM Tris-HCl buffer, pH 8.0,
containing 5 mM calcium chloride or 10 mM EDTA (negative
control for MMP activity). Gels were stained in 50% methanol,
10% acetic acid containing 0.1% Coomassie Blue R250 and
imaged on a BioRad Chemidoc XRS.
Human Samples
Via ultrasound-guided amniocentesis, 16–22 week gestation
amniotic fluids (AFs) were obtained from healthy women (average
age 27.766.6) carrying fetuses with (n=17) and without (n=16)
cardiac defects from 2004–2007 at Yale New Haven Hospital. The
Human Investigation Committee of Yale University approved our
study protocol, and written informed consent for research purpose
was obtained from all participants before the procedure. The
purpose of the amniocentesis was clinical: to rule out chromosomal
abnormalities. Criteria for the ‘‘diseased group’’ were heart defect
visualized on at least two ultrasound exams. In cases resulting in
live newborns, the defects were confirmed postnatally. In the
remaining cases, the pregnancy course was terminated and the
defect was confirmed in elected autopsies. CHDs included
ventricular septal defects, valvular stenosis, complete atrioventric-
ular septal defects, bilateral ventriculomegaly, hypoplastic ventri-
cle, tetralogy of Fallot, and transposition of the great arteries.
Criteria for the ‘‘non-diseased group’’ were AF samples from
women undergoing genetic testing who had a normal course of
pregnancy including term delivery. All fetuses in the non-diseased
group were euploid and had normal heart ultrasound examina-
tions during pregnancy and a normal physical exam at birth.
Frozen AFs were centrifuged and aliquoted prior to assay.
Western Blot was performed as described above on 25 mg of AF. A
‘‘standard’’ control sample was chosen to run on each gel.
Coomassie staining of gels confirmed equal protein load. Films
were scanned and analyzed in Quantity One as follows. Bands
were selected for quantification using the automated volume
contour tool. Band densities were calculated by computer
algorithm as the volume, the sum of pixel intensities multiplied
by pixel area, adjusted by global background subtraction. Blotting
and analysis was performed by a blinded observer.
Univariate logistic regression was performed using the design
packet in R (GNU S). The AF measurements were log-
transformed using log2 and the regression coefficient and odds
ratio (OR) were calculated. The OR can be interpreted as the
increased risk of developing a cardiac defect per doubling of the
AF measurement. The mean classification error was calculated
using 10 by 10 cross-validation. An attempt to perform multiple
regression analysis did result in inflated regression coefficient
estimates due to strong multicollinearity. After normalization and
centering of all biomarker data, Principle Component Analysis
(PCA), a clustering tool that reduces multidimensional data sets to
identify new meaningful underlying variables, was performed
using the SVD function in Matlab.
Results
Tissue Samples from a Murine Model of Induced
Cardiovascular Defects
One premise of our study is that proteomic profiling of
hyperglycemia exposed vascular tissue will enrich for factors
Cardiovascular Protein Cluster
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cemia was used as an ‘‘inducer’’ because increased vascular and
cardiac defects are observed in the offspring of diabetic rodents
(streptozotocin-induced) and the infants of diabetic women
[26,27,28]. Interestingly, pregnant women presenting with altered
diurnal gylcemic profiles not related to diabetes also have a higher
incidence of preterm labor, fetal malformations and perinatal
mortality similar to diabetic patients, underscoring the devastating
developmental effects of hyperglycemia [29]. The addition of
20 mM D-glucose (a plasma concentration of glucose often
observed in both human and rodent diabetics during a
hyperglycemic episode) to ex vivo embryo cultures results in
vasculopathy in the yolk sac and inhibition of EMT in the cardiac
endocardium [23,30,31,32,33,34]. These studies contribute to
accumulating evidence that transient hyperglycemia directly
affects the endothelium, and highlight the importance of
endothelial cell homeostasis during embryonic development [35].
Identification of candidate differentially expressed proteins
between normal and hyperglycemic groups will provide insight
into currently unrecognized proteins in cardiovascular develop-
ment and may allow for the discovery of biomarkers of CHDs
applicable to the general population.
Under normoglycemic conditions, control embryos exhibit
normal organogenesis and vascular development of the yolk sac
(Fig. 1A, whole embryo inside a functional yolk sac containing
circulating red blood cells). Hyperglycemic embryos display
malformation of the embryo proper and yolk sac vasculature
(Fig. 1B, abnormal embryo with a nonfunctional vitelline
circulation, evidenced by pooling of blood at one pole of the yolk
sac). Whole mount staining of control yolk sacs for the endothelial
marker PECAM-1 confirms the formation of a mature, remodeled
vasculature with a hierarchy of arborizing large and small vessels
(Fig. 1C) while hyperglycemic yolk sacs appear arrested at the
primary capillary plexus stage of vascular development (Fig. 1D).
By E9.5, endocardial cells (cardiac endothelial cells) of the
endocardial cushions are actively undergoing EMT and invading
the cardiac jelly in control embryos (Fig. 1E). Hyperglycemia
results in an acellular endocardial cushion due to inhibition of
EMT, which prematurely arrests cushion morphogenesis (Fig. 1F).
We hypothesized that the hyperglycemic insult may be used to
enrich for factors involved in endothelial differentiation/dysfunc-
tion. Due to the global biological effects of hyperglycemia, we
expected a large number of proteins to exhibit expression changes,
but only a subset to be relevant to endothelial differentiation/
dysfunction. Therefore two additional groups, ‘‘rescue condi-
tions’’, were included in the experimental design. Our previous
studies demonstrated that exogenous rVEGF-A165 or a nitric oxide
donor supplementation reverses the morphological, functional and
biochemical changes induced by hyperglycemia in the cardiovas-
cular system [23,36,37]. Thus, we hypothesized that the proteins
dysregulated by hyperglycemia but returned to normal levels by
both rVEGF and nitric oxide donor represent a set of proteins that
are important for normal vascular development.
Liquid Chromatography Mass Spectrometry (LC-MS) of
Yolk Sac Tissue
Groups of ten 7.5 dpc conceptuses were cultured in normogly-
cemia, hyperglycemia, hyperglycemia plus rVEGF-A165, or hyper-
glycemia plus nitric oxide donor. Yolk sacs were harvested at
24 hours, at the end of the primary capillary plexus stage and
beginning of the vascular remodeling stage, and processed
individually for mass spectrometry. LC-MS detected 39,120 peaks
which were subsequently analyzed using MZmine software [24,25].
To increase confidence, a data reduction step discarded peaks
detected in less than 5 samples resulting in 12,908 peptide peaks in
the intensity matrix (Table S1). Data alignment, normalization and
statistical treatment revealed 651 differentially regulated peaks
between normal and hyperglycemic samples. Among those, 143
were dysregulated (upregulated or downregulated) by hyperglyce-
mia and returned to control levels by both the rVEGF and nitric
oxide donor groups. These 143 peaks were targeted (in an aliquot of
the original yolk sac lysate sample) for MS-MS fragmentation and
subsequent protein identification using the Mascot search engine
(www.matrixscience.com) and NCBInr Database.
To globally visualize the dataset, volcano plots were generated
depicting each of the 12,908 peptide peaks as a point and plotting
Figure 1. Experimental Model: Applying Proteomic Profiling to
a Hyperglycemia Induced Model of Cardiovascular Defects.
Embryos cultured ex vivo exhibit normal organogenesis and vascular
development (A, normal embryo inside a functional yolk sac containing
circulating red blood cells). Embryos treated with 20 mM D-glucose
display malformation of the embryo and vasculature (B, abnormal
embryo and pooling of blood at one pole). PECAM staining of control
yolk sacs reveals a mature, remodeled vasculature (C) while hypergly-
cemic yolk sacs appear immature and mal-developed (D). Normally by
E9.5, EMT has begun within the cardiac endocardial cushions (E).
Treatment with hyperglycemia results in an acellular endocardial
cushion (F). E–F: a-Smooth muscle cell actin (green) labeling of the
myocardium (Myo) and mesenchymal cells (Mes); PECAM (red) staining
of the endocardium (En); CJ (Cardiac Jelly). Volcano plots (G–I))
depicting each peptide peak detected by LC-MS as a blue dot and
plotting the log2 ratio (of treatment to control) against 2log10 p value
(G, HG vs Control; H, HG+rVEGF vs Control; I, HG+ nitric oxide donor vs
Control). The red dots represent the 143 peptide peaks that were
dysregulated by hyperglycemia but returned to control levels by both
rVEGF (H) and nitric oxide donor (I). The red horizontal lines are drawn
at p=0.05 and the red vertical lines are drawn at log2 ratio=1 and 21.
Scale bars=100 mm. (A–B is reprinted from Am J Pathol 2001, 158:1199-
206 with permission from the American Society for Investigative
Pathology.)
doi:10.1371/journal.pone.0004221.g001
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value (Fig. 1G–I). The red dots in the volcano plots represent the
143 peptide peaks that are dysregulated by hyperglycemia
[inclusion criteria: both p,0.05 and log2 (fold change).1] but
returned to control levels by both rVEGF and nitric oxide donor
[inclusion criteria: p.0.05 or p,0.05 and log2 (fold change),1].
Significant peptide peaks were ranked by fold change and those
greater than or equal to 2 [log2 (fold change)$1] were included.
Of the 143 peptide peaks, approximately 75% were upregulated.
The majority of peptide peaks display a 2–4 fold change [log2 (fold
change)$1–2]. Though these changes appear minor, in develop-
mental contexts slight changes in growth factors or signaling
pathways disrupt cardiovascular development. For instance, a one
fold increase or half fold decrease in VEGF leads to lethal cardiac
defects [38].
Protein Identification of the Subset of Peptide Peaks
Dysregulated by Hyperglycemia But Returned to Normal
Levels by Both rVEGF and Nitric Oxide Donor
Candidate proteins with the highest Mowse score [39] were
mapped onto Gene Ontology classes in order to group proteins
according to biological processes (Table 1) [40]. Candidates
included distinct collagen and laminin chains which are known to
surround vessels and provide environmental cues to endothelial
cells [41]. Extracellular matrix (ECM) and provisional matrices,
including the cardiac jelly, contain laminin, collagen and other
ECM molecules many of which are also known to be expressed in
human amniotic fluid (AF). Interestingly, patients with diabetic
retinopathy secrete into the circulation a detectable increase in the
level of laminin, suggesting that it may be a useful biomarker [42].
Proteoglycans are also present in the vasculature and the
endocardial cushions, therefore it was not surprising to find
chondroitin 6 sulfotransferase 3 (CHST3), an enzyme that sulfates
proteoglycans, as one of the dysregulated proteins in our dataset.
Several proteins in our dataset mapped to the Gene Ontology
term ‘‘Proteolysis’’. These proteins function in varied biological
processes involving proteolytic activity such as cell-cell adhesion,
migration/invasion, matrix remodeling, growth factor release/
activation, receptor shedding and cytokine signaling. The
candidate proteases detected, included ADAM15, MMP2, Sup-
pressor of tumorigenicity 14 (ST14) and Proprotein convertase 1
(Pcsk1).
A number of candidate proteins that directly affect differenti-
ation and embryonic development were discovered in our dataset,
including Hairy and enhancer of split 6 (HES6), Notch1, NOGO-
A, Jumonji, and WNT16. Several other candidate proteins
identified in our screen mapped to the Gene Ontology term
‘‘Transport’’ including Transient receptor potential protein
(TRPC5), a calcium channel, Sodium/vitamin C transporter
(SVCT or Slc23a1), a sodium/ascorbate cotransporter, and ATP
binding proteins (Atp13a1, Acca13, and Abca7). Other proteins of
note found in our database include Fbxo42 (part of the ubiquitin
ligase complex), Protein inhibitor of activated STAT4 (PIASc)( a
SUMO ligase), Kinesin-like protein KIF21b (a microtubule
binding motor protein), Enolase 1 (an enzyme in the glycolysis
pathway) and Microrchidia 2a (Morc2a or ZCWCC1).
Several candidate factors in our dataset have been correlated
with disease states including the Ets family member Elf5, which is
upregulated in breast cancer [43]. Interestingly, the bHLH
transcriptional repressor Single-minded 2 which is thought to
contribute to the etiology of Down syndrome [44] and Down
syndrome critical region gene 3 (DSCR3), located on human
chromosome 21, were present in our dataset. Approximately, 40–
50% of infants with Down syndrome have CHDs. Finally, protein
tyrosine phosphatase, non-receptor type 1 (PTPN1) was identified
in our dataset. PTPN1 plays a role in obesity and metabolism.
Further, gene variants have been identified in obese people and
type 2 diabetics [45,46,47].
In order to assess the biological significance of the dysregulation
of these candidate proteins and validate our MS-MS results (Fig. 2),
Western blotting was performed on lysates of yolk sacs harvested
from embryos cultured under the four experimental conditions.
ADAM15, Pcsk1, and NOGO-A were confirmed to be downreg-
ulated while Laminin, TRPC5, WNT16, Morc2a, and CHST3
were confirmed to be upregulated. Additionally, a reduction in the
proteolytic activity of MMP2 was observed by zymography. After
hyperglycemia treatment, the change in expression of most
proteins was 2 fold: densitometry of the blots displayed in
Figure 2 detected a fold change decrease of 1.9 for MMP2,
decrease of 2.7 for ADAM15, increase of 2 for ST14, and decrease
of 1.9 for Pcsk1 in the HG group. These differences are consistent
with the mass spectrometry analysis (Figure 1G–I and Table S1)
which revealed that the majority of peptide peaks display a 2–4
fold change. Additional proteins that displayed the expected fold
change included WNT16, Jumonji, TRPC5, SVCT, NOGO-A,
Fbxo42, Enolase1, and Morca2a. The only protein that validated
but did not demonstrate the predicted fold change was Laminin.
These data contribute to the accumulating evidence of the
accuracy of label-free LC-MS measurements to predict relative
protein changes [48,49]. Several identified proteins did not
validate by Western blot and were not pursued further. Several
other proteins were not pursued because no commercially
available antibodies were available for validation and subsequent
investigation.
We discovered a number of unnamed and predicted proteins
with significant dysregulation. Continued curation of the public
databases will reveal the identities and functions of unnamed
proteins identified from cDNA initiatives; however, as little
information is currently available on such proteins these were
not further pursued. Many proteins were identified from multiple
different significant peptide peaks (i.e. different fragments within
the same protein). The consolidated list consisting of 44 proteins is
presented in Table 1 (excluding unnamed and predicted proteins).
Factors Involved in Yolk Sac Vascular Development Are
Also Important for Cardiac Development
To validate our assumption that proteins relevant to cardiac
development may be isolated from vascular tissue, proteins from
the validated candidate list were tested by immunofluorescence
microscopy for their presence in the endocardial cushion at E9.5 (a
stage of cardiac development when EMT is actively occurring).
This is a time and place during cardiogenesis that is widely
recognized to be a ‘‘hot spot’’ of cardiac anomalies.
Laminin 1 was strongly present at the interface of the
myocardial and mesenchymal zones of the cushion, consistent
with basement membrane localization (Fig. 3A). TRPC5 and
SVCT were highly expressed in the compact myocardium and
weakly/absent throughout the rest of the myocardium and
cushion (Fig. 3B, C). Potentially these factors play a role in
contraction or function of the valves. NOGO-A localizes strongly
within the myocardium while staining with a NOGO-A/B
antibody reveals localization within the mesenchymal and
endothelial cells, suggesting NOGO-B presence in these cell types
(Fig. 3D, E). b-galactosidase staining of transgenic lacZ NOGO-
A/B whole hearts harvested at E9.5 demonstrated localization to
the outflow tract and atrioventricular canal (Fig. 3F). CHST3,
WNT16, and ST14 were detected throughout the cell layers of the
endocardial cushion and in the myocardium (Fig. 3G–I). Jumonji
Cardiovascular Protein Cluster
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Category Protein Name
Entrez
GeneID Gene Ontology Processes
Adhesion/ Migration Chemokine (C-X-C motif) ligand 15 (Cxcl15) 20309 Chemotaxis; hemopoiesis; signal transduction; immune response
Chondroitin 6-sulfotransferase (Chst3) 53374 Carbohydrate metabolic process
Collagen, type IV, alpha 2 (Col4a2) 12827 Cell adhesion; phosphate transport
Collagen, type VII, alpha 1 (Col7a1) 12836 Cell adhesion; phosphate transport
Laminin, alpha 4 chain (Lama4) 16775 Cell adhesion; blood vessel development; regulation of embryonic
development
Matrix metalloprotease 2 (Mmp2) 17390 Blood vessel maturation; collagen catabolic process; proteolysis
NOGO-A (Rtn4) 68585 Regulation of cell migration; angiogenesis; nervous system development
Proprotein convertase 1 (Pcsk1) 18548 Peptide biosynthetic process; proteolysis
Suppressor of tumorigenicity 14 (St14) 19143 Cell migration; proteolysis
Cytoskeleton Dishevelled associated activator of morphogenesis 2
(Daam2)
76441 Actin cytoskeleton organization and biogenesis
Filamin C, gamma (actin binding protein 280) (Flnc) 68794 Actin filament-based process
Kinesin family member 21B (Kif21b) 16565 Microtubule-based movement
Tubulin, alpha 1B (Tuba1b) 22143 Microtubule-based movement
Differentiation/
Development
E74-like factor 5 (Elf5) 13711 Ectoderm development; transcription
Hairy enhance of spilt 6 (Hes6) 55927 Cell differentiation; transcription
Jumonji, AT rich interactive domain 2 (Jarid2) 16468 Multicellular organismal development; transcription
Laminin, alpha 4 chain (Lama4) 16775 Blood vessel development; cell adhesion; regulation of embryonic
development
Notch1 18128 Cell differentiation; heart development; EMT; angiogenesis
NOGO-A (Rtn4) 68585 Nervous system development; angiogenesis; regulation of cell migration
Protein inhibitor of activated STAT, 4 (Pias4) 59004 Multicellular organismal development; JAK-STAT cascade; transcription;
protein sumoylation
Single-minded 2 (Sim2) 20465 Cell differentiation; nervous system development; transcription
WNT16 93735 Multicellular organismal development
Insulin Signaling Proprotein convertase 1 (Pcsk1) 18548 Peptide biosynthetic process; proteolysis
Protein tyrosine phosphatase, non- receptor type 1
(Ptpn1)
19246 Insulin receptor signaling pathway; Dephosphorylation
Zinc finger protein 106 (Zfp106) 20402 Insulin receptor signaling pathway
Adaptor-related protein complex 3, beta 1 subunit
(Ap3b1)
11774 Antigen processing/presentation; protein transport; endocytosis
Chemokine (C-X-C motif) ligand 15 (Cxcl15) 20309 Immune response; chemotaxis; hemopoiesis; signal transduction
Interleukin 25 (Il25) 140806 Inflammatory response
Proteolysis A disintegrin and metalloproteases 15 (Adam15) 11490 Proteolysis; integrin-mediated signaling
Proprotein convertase 1 (Pcsk1) 18548 Proteolysis; peptide biosynthetic process
Matrix metalloprotease 2 (Mmp2) 17390 Proteolysis; blood vessel maturation; collagen catabolic process
Suppressor of tumorigenicity 14 (St14) 19143 Proteolysis; cell migration
Signal Transduction A disintegrin and metalloproteases 15 (Adam15) 11490 Integrin-mediated signaling; proteolysis
Chemokine (C-X-C motif) ligand 15 (Cxcl15) 20309 Signal transduction; chemotaxis; hemopoiesis; immune response
Protein inhibitor of activated STAT, 4 (Pias4) 59004 JAK-STAT cascade; multicellular organismal development; transcription;
protein sumoylation
Protein kinase C binding protein 1 (Prkcbp1) 228880 Phosphorylation
Protein tyrosine phosphatase, non- receptor type 1
(Ptpn1)
19246 Dephosphorylation; insulin receptor signaling pathway
Transcription/
Translation
DEAD (Asp-Glu-Ala-Asp) box polypeptide 31 (Ddx31) 227674 RNA processing
E74-like factor 5 (Elf5) 13711 Transcription; Ectoderm development
Hairy enhance of spilt 6 (Hes6) 55927 Transcription; Cell differentiation
Jumonji, AT rich interactive domain 2 (Jarid2) 16468 Transcription; Multicellular organismal development
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weakly in the endocardium (Fig. 3J). The expression pattern of
Enolase 1 was localized to the endocardium, mesenchyme, and
epicardium, but absent from the myocardium (Fig. 3K). ADAM15
was highly expressed in the endocardium and mesenchymal cells,
but also present in the myocardium (Fig. 3K, L). NOGO-B, ST14,
Enolase 1, and ADAM15 had a notable presence within the
cellular projections of the mesenchymal cells. Immunoreactivity
for Pcsk1 was strongest in the myocardium and weaker in the
endocardium and mesenchyme (Fig. 3M). Fbxo42 displayed
nuclear expression in a gradient pattern across the layers of the
cushion to the myocardium (Fig. 3N). The zinc finger protein,
Morc2a, was present in an increasing gradient from the
endocardium to the mesenchymal cells to the myocardium, and
most intensely in a nuclear/perinuclear pattern (Fig. 3O).
Proteins were selected for further study in a functional assay, the
ex vivo atrioventricular canal assay, that has yielded many insights
into the molecular events that underlie endocardial cushion
development [4]. The atrioventricular canal assay mimics the
spatiotemporal, molecular and biochemical events that occur
during in vivo valve development and provides a system amenable
to experimental manipulation [50,51]. In this model, the
atrioventricular canal segment is excised prior to EMT; the
cushion tissue is exposed and placed onto the surface of a collagen
gel. Media containing preservative free antibodies directed against
secreted proteins or the extracellular domain of membrane
proteins is added to the cultures. The endothelial cells migrate
onto the surface of the gel and away from the explants. In response
to inductive signals secreted by the myocardium a subset of the
endothelial cells undergo EMT and invade into the gel. Cells
undergoing EMT follow a semi-linear progression of morpholog-
ical changes including: 1) lateral cell-cell separation from epithelial
sheets, 2) elongation of the single, rounded cells on the surface of
the gel, and 3) invasion of elongated cells into the gel (Fig. 4K).
Approximately 300 cells migrate out of each of the explants,
however in order to observe the cellular morphology in detail, a
high magnification image of few cells is displayed in Figure 4.
Additionally, a cartoon representation of these cells is provided to
highlight the varied and detailed cellular morphologies observed in
this assay.
Normal cultures (IgG treatment) exhibited the characteristic
phenotype of EMT, displaying elongated, invasive mesenchymal
cells (Fig. 4A, C, E, G and I; images taken below the gel surface).
However a dramatic inhibition of cardiac EMT resulting in the
majority of cells maintaining an epithelial phenotype (rounded and
non-invasive) was observed with WNT16 sequestration (Fig. 4B;
gel surface image). In the yolk sac, an up regulation of WNT16
was associated with mal-development (abnormal increase in
endothelial cells) while in the atrioventricular canal an inhibition
of WNT16 was associated with decreased differentiation, suggest-
Category Protein Name
Entrez
GeneID Gene Ontology Processes
Protein inhibitor of activated STAT, 4 (Pias4) 59004 Transcription; JAK-STAT cascade; multicellular organismal development;
protein sumoylation
Ribosomal protein L18 (Rpl18) 19899 Translation
Serine/arginine repetitive matrix 2 (Srrm2) 75956 RNA splicing
Single-minded 2 (Sim2) 20465 Transcription; cell differentiation; nervous system development
SRY-box containing gene 19 (Sox19) 20673 Regulation of transcription
Transport Adaptor-related protein complex 3, beta 1 subunit
(Ap3b1)
11774 Protein transport; endocytosis; antigen processing/presentation
ATPase type 13A1 (Atp13a1) 170759 Cation transport; metabolic process
ATP-binding cassette transporter, sub- family A,
member 13 (Abca13)
268379 Transport; protein targeting
ATP-binding cassette, sub-family A, member 7 (Abca7)27403 Transport; phagocytosis
Collagen, type IV, alpha 2 (Col4a2) 12827 Phosphate transport; cell adhesion
Collagen, type VII, alpha 1 (Col7a1) 12836 Phosphate transport; cell adhesion
Down syndrome critical region gene 3 (Dscr3) 13185 Vacuolar transport
Solute carrier family 23 (nucleobase transporters),
member 1 (Slc23a1)
20522 Ion transport
Transcobalamin 2 (Tcn2) 21452 Ion transport
Transient receptor potential protein 5 (Trpc5) 22067 Ion transport
Others/Unknown Enolase 1, alpha non-neuron (Eno1) 13806 Glycolysis
F-box protein 42 (Fbxo42) 213499 Ubiquitin cycle
TNF receptor-associated protein 1 (Trap1) 68015 Protein folding; response to stress
Microrchidia 2a (Morca2a) 74522 ?
T complex expressed gene 4 (Cramp1l) 57354 ?
T complex protein-10 (Tcp10) 21458 ?
Tetratricopeptide repeat domain 15 (Ttc15) 217449 ?
Tripartite motif containing 68 (Trim68) 101700 ?
doi:10.1371/journal.pone.0004221.t001
Table 1. cont.
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cell adhesion using a collagen IV antibody led to the formation of
epithelial cells with a rounded morphology and the presence of
short cellular projections (Fig. 4D; gel surface image).
Blocking NOGO binding using a NOGO-A/B antibody
directed against its extracellular domain revealed a novel role for
NOGO in cardiac development. The treated cells appear to
undergo a partial EMT or prematurely arrested EMT as
evidenced by the formation of oval cells rather than fully
elongated cells (Fig. 4F; gel surface image). However, given the
known roles of NOGO in the neuronal system, a guidance or
matrix interaction defect may underlie the observed phenotype. At
this time it is unclear if this effect is due to NOGO-A or NOGO-B
as the antibody used in these studies detects both isoforms.
NOGO-A was the isoform identified in our MS dataset however
our localization data suggest NOGO-B is expressed by the
endocardium and mesenchyme. Further, a recent paper demon-
strated a role for NOGO-B in vascular cell biology [52].
Atrioventricular canals cultured in the presence of an antibody
directed against the ectodomain of ADAM15 resulted in blunted
cardiac EMT (Fig. 4H; gel surface image) compared to IgG control.
The cells begun to elongate and displayed multiple cellular
extensions in a star-like pattern, but failed to complete elongation
and invade the gel. Antibody blocking of the extracellular domain of
SVCT failed to reveal a role for this transporter in EMT processes
(Fig. 4J; image taken below the gel surface). Collectively, these results
demonstrate that several proteins in our dataset are present in the
embryonic heart and have novel roles at various steps of cardiac
EMT, confirming that our approach utilizing vascular tissue did
identify proteins relevant to cardiac development.
Identification of Biomarkers of Human Congenital Heart
Defects
One of the aims of this study was to identify biomarkers that
discriminate diseased from healthy fetuses using the proteomic
dataset as a guide for candidate proteins that require follow up
with more precise protein chemistry methods (Western blot,
immunoflourescence microscopy, and explant assays). A pilot
study was initiated to determine if the expression of these proteins
vary in the AF of a cohort of healthy, non-diabetic pregnant
women. AF was obtained from routine amniocentesis of women
carrying normal fetuses (n=17) and women carrying fetuses with
CHDs (n=16) (population details in Materials and Methods). The
levels of candidate biomarkers in the AF were assessed by Western
blot followed by densitometry.
CHST3 was significantly (p,0.01) increased in the AF of
women carrying fetuses with CHDs (mean=380) compared to
controls (mean=176) by Student’s t-test (unpaired; two-tailed
distribution; two-sample equal variance), but not significant by
univariate logistic regression (p,0.1; misclassification error of
0.33) (Fig. 5A, B; Table 2). Morca2a demonstrated an increased
trend in the AF of women carrying fetuses with CHDs
(mean=505) compare to controls (mean=374); however, this
finding was not significant by t-test (p,0.1) nor univariate logistic
regression (p,0.2, misclassification error of 0.35).
The biomarkers that showed significant association with CHDs
in univariate logistic regression were WNT 16, Pcsk1 and ST14
(Table 2). WNT16 was significantly increased (p=0.006) in the AF
of women carrying fetuses with CHDs (mean=818) compared to
controls (mean=220) as was Pcsk1 (p=0.012; mean=167
compared to control mean=50), and ST14 (p=0.013;
Figure 2. Validation of Differential Expression of Candidate Proteins Identified in the Proteomic Profiling Study. To validate candidate
proteins detected by LC-MS-MS, Western blotting and zymography was performed on lysates of yolk sacs harvested from embryos cultured under the
four experimental conditions. Erk2 was used as a loading control. Green arrows represent protein levels that increased with hyperglycemia (HG)
treatment but returned to control levels in both rescue conditions (HG/V and HG/NO). Red arrows represent protein levels that decreased with
hyperglycemia treatment but returned to control levels in both rescue conditions (HG/V and HG/NO). The Phi symbols represent protein levels that
did not vary across treatment groups or did not vary in the expected pattern (increased or decreased by HG and returned to control levels in both
rescue conditions).
doi:10.1371/journal.pone.0004221.g002
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cross-validation experiment, these markers were able to correctly
classify controls from cases in up to 89% of cases (misclassification
error of 0.11). Proteins that did not appear to be predictive for
heart defect included SVCT, Enolase and PIASc. PCA analysis
using all biomarkers revealed clustering of controls and cases
(Fig. 5C) demonstrating that the CHD samples segregate from the
controls. Although a larger cohort is required to confirm the
specificity and sensitivity of these markers for diagnosis, our pilot
study of human AF revealed promising biomarkers able to detect a
range of CHDs (ventricular septal defects, valvular stenosis,
complete atrioventricular septal defects, tetralogy of Fallot, and
transposition of the great arteries) that in part result from defects in
cushion morphogenesis. Furthermore, dysregulation of WNT16,
ST14 and Pcsk1 may reflect the molecular origins of CHDs.
Discussion
Applying a proteomic approach to embryonic vascular tissue
generated from an ex vivo model of vasculopathy, we have
identified proteins and pathways that are disrupted during
cardiovascular development and lead to the observed pathological
phenotype. Dysregulation of this set of proteins in a ‘‘normal’’
fetus may signal that the fetus is congenitally at risk or
encountering an environmental stressor. Several of these protein
targets (WNT16, Pcsk1 and ST14) provided the basis for a novel
Figure 3. Spatial Expression Pattern of Validated Proteins in in vivo Embryonic Hearts. Immunofluorescence (red or green) was performed
on hearts excised at E9.5 to confirm that the validated proteins identified in the vascular dataset are also present in the heart (A–E, G–O). Insert
contains the DAPI (blue) merged image. F: Whole mount b-gal staining of an E9.5 NOGO-A/B-lacZ heart. Outflow Tract (OFT); Ventricle (V); AVC
(Atrioventricular Canal); A (Atrium); Myocardium (Myo); Endocardium (En); Mesenchyme (Mes); Scale bar=50 mm.
doi:10.1371/journal.pone.0004221.g003
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tion of WNT16, ST14 and Pcsk1 may play a role in the etiology of
human CHDs. Several forms of CHDs are known to have a
genetic basis such as microdeletions (22q11) in DiGeorge
Syndrome and single gene mutations (JAG1) in Alagille Syndrome.
It would be of interest to determine if individuals with CHDs carry
genetic mutations in WNT16, ST14 or Pcsk1. At the protein level,
these markers are overexpressed therefore if sequence variants are
found mutations would likely affect protein function and/or
activity. In the case of ST14 and Pcsk1, both of which are
enzymes, a hypomorphic or hypermorphic mutation in these genes
has the potential to affect multiple substrates and hence several
cellular processes.
Changes in cellular processes not only reflect the molecular
origins of disease but also provide avenues for molecular therapies
to ameliorate the defect. To this end, we identified several
proteins, previously unknown to have a role in cardiovascular
development, with diverse functions that cluster to adhesion/
migration, differentiation, transport, IGF signaling pathways
(Table 1). Although we discovered and characterized several
proteins with currently unknown roles in cardiovascular develop-
ment, we were able to place them in their relevant biological
context by relating them to existing functional cascades (signaling,
enzymatic, polarity, migration, and differentiation). Protein
networking analysis revealed that several of the identified proteins
interact upstream or downstream of each other and with
established factors in cardiovascular development (Fig. 6). The
presence of proteins known to have roles in cardiac development
within our dataset further validates our approach. For example,
our screen detected the transcriptional repressor Jumonji whose
deletion is known to result in myocardial defects and ventricular
septal defects [53]. However our data demonstrating decreased
Jumonji during vasculopathy extends the role of Jumonji to
vascular development.
Figure 4. Analysis of the Potential Biological Function of
Identified Proteins in an ex vivo Cardiac Assay. The potential
biological effects of identified proteins were characterized in the ex vivo
atrioventricular canal assay to determine if proteins relevant to cardiac
development may be isolated from the vascular dataset. Control IgG (A,
C, E, G and I) or antibodies directed against WNT16 (B), Collagen IV (D),
NOGO-A/B (F), ADAM15 (H), and SVCT (J) were added to the media
bathing the explants. After 48 hours F-Actin (red) staining was
performed and a high magnification image of a few representative
cells was taken (blue=DAPI). Cartoons representing the various stages
of EMT (K) and the morphology of the cells within the high
magnification image from each treatment are displayed. Scale
bar=50 mm.
doi:10.1371/journal.pone.0004221.g004 Figure 5. Identification of Biomarkers of Human Congenital
Heart Defects. Densitometry data (A) from Western blots of AF [CHDs
(HD) N=17; Controls (C) N=16]; black bars represent the mean.
Coomassie stained gel of AF samples and representative Western blots
for WNT16, Pcsk1, ST14, and CHST3 on a sampling of patients (B). PCA
plot (C) for all biomarkers demonstrates separation of CHDs samples
from controls. Red (Control); Blue (CHD).
doi:10.1371/journal.pone.0004221.g005
Table 2. Univariate Logistic Regression and Misclassification
Error for Amniotic Fluid Biomarkers.
Marker Coefficient p-Value OR 95% CI MC error
Wnt16 2.71 0.006 15.01 2.16–104.44 0.11
SVCT 0.62 0.252 1.86 0.64–5.35 0.41
Pcsk1 3.29 0.012 26.95 2.07–350.70 0.12
CHST3 0.51 0.129 1.67 0.86–3.22 0.33
Enolase 20.43 0.213 0.65 0.33–1.28 0.59
PIAS 0.46 0.209 1.58 0.77–3.21 0.63
ST14 1.97 0.013 7.17 1.51–34.14 0.19
Morca2a 0.58 0.213 1.78 0.72–4.41 0.35
doi:10.1371/journal.pone.0004221.t002
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associated with increased nitric oxide, however the nitric oxide
targets remained elusive [36]. Recently nitrosylation sites on the
cytoplasmic domain of TRPC5 were identified and in response to
nitric oxide, Ca(2+) entered bovine aortic endothelial cells [54]. In
this study we observed increased TRPC5, raising the possibility
that the observed yolk sac vasculopathy is mediated by nitric oxide
driven over-activation of TRPC5. We speculate that the
subsequent abnormal influx of calcium through TRPC5 activates
the calcineurin/NFAT pathway [55]. In the developing heart, the
NFAT pathway is tightly regulated and has complex interactions
with DSCR (another protein identified in our screen) and VEGF
to drive differentiation; low levels of VEGF are required for EMT
while high levels terminate it [56,57]. Therefore, it is tempting to
speculate that TRPC5 is a novel player in cardiac development,
acting upstream of NFAT, leading to dysregulation of VEGF
expression and ultimately termination of heart development.
On the other hand, positive regulation of cardiac EMT relies on
Wnt/b-catenin signaling however the specific Wnts involved are
largely unknown with the exception of Wnt9a in the avian heart
[58]. Variations in Wnt signaling are expected to have direct
effects on valve plasticity as canonical Wnt/b-catenin signaling
induces mesenchymal differentiation and modulates the amount of
mesenchyme produced [59,60]. One defect associated with
vasculopathy is increased endothelial cell number per vessel,
leading to a hypertrophic, nonfunctional capillary plexus. Thus the
observed upregulation of WNT16 may lead to unregulated
endothelial cell differentiation or proliferation, ultimately affecting
the organization of vascular structures. Concomitantly, antibody
neutralization of WNT16 blunts cardiac EMT in the atrioven-
tricular canal assay. Though the WNT16 isoform is known to be
expressed in the embryonic heart [61], a functional role for
WNT16 has not been previously reported, thus our atrioventric-
ular canal assay results describes a new function for a novel WNT
member in the cardiac developmental cascade. Additionally, we
observed increased WNT16 in human amniotic fluid (AF) of
women carrying fetuses with CHDs and demonstrated that this is
predictive of CHDs. Monitoring WNT16 levels and targeting
WNT16 signaling may provide novel avenues for future diagnostic
and pharmacological research.
Proteoglycans and extracellular matrix are important players in
cell adhesion, migration, proliferation, and angiogenesis, processes
important in both development and disease. CHST3 catalyzes the
transfer ofsulfatetoposition 6ofthe N-acetylgalactosamine(GalNAc)
residue of chondroitin. Human endothelial cells express CHST3
mRNA while endothelial cells overlying the porcine mitral valve
produce chondroitin sulphate [62,63]. Interestingly, gain of function
experiments with the heart development regulatory gene Tbx20in the
avian endocardial cushion resulted in decreased chondroitin sulfate
proteoglycans and increased mesenchyme [64]. Our data demon-
strating CHST3 expression in the murine endocardial cushion
suggests that this may be a conserved mechanism to regulate
mesenchyme production, although further studies are required to
confirm this hypothesis. Though not predictive of CHDs, CHST3
was dysregulated in the AF of woman carrying fetuses with CHDs,
suggesting a role in cardiac development.
An additional factor involved in adhesion/migration identified
in our study is the protease ADAM15. Multiple individual ADAM
isoform KO mice display cardiac defects, including Adam 9, 17,
and 19 [65,66,67]. ADAM15 is expressed in blood vessels and
endocardium, and although ADAM15 mice are viable studies
using retinopathy and tumor angiogenesis models demonstrate an
inducible vascular phenotype (failure of remodeling of the primary
capillary plexus) [68]. In conjunction, our data indicates that
decreased ADAM15 enzymatic activity in the hyperglycemic yolk
sacs disrupts growth factor/cytokine signaling of a yet unknown
pathway, resulting in an inability of the endothelial cells to initiate
remodeling, consistent with the previous report on an inducible
vascular phenotype. Our data from the atrioventricular canal
assay extends the known functions of ADAM15 to include cardiac
EMT. Speculating on the substrates involved in its effects on
differentiation to mesenchymal cells, ADAM15 proteolytic activity
on cadherins is one plausible target [69]. Further, the strong
immunofluorescent staining of ADAM15 in the cellular projec-
tions of cardiac mesenchymal cells suggests ADAM15 may be
necessary for cell interaction with the matrix potentially via
Figure 6. Integration of Proteins Identified by Proteomic Profiling with Known Pathways and Biological Processes Involved in
Cardiovascular Development. We identified proteins (in red) known and previously unknown to have roles in cardiovascular development with
diverse functions including migration, differentiation, IGF signaling, protease activity and transport (Table 1). Several of the proteins interact upstream
or downstream of each other and with established factors in cardiovascular development. Dysregulation of these proteins/pathways not only reflect
the molecular origins of CHDs but, in a normal fetus, may signal that the fetus is at risk or encountering an environmental stressor thus providing the
basis for novel diagnostic tests.
doi:10.1371/journal.pone.0004221.g006
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determine if ADAM15 is predicative of CHDs. Interestingly,
ADAM12 is a known biomarker for Down syndrome, demon-
strating the applicability of this family to biochemical assays for
diagnosis [70]. The novel finding of a functional role for ADAM15
in the embryonic heart combined with its strong expression in the
cardiovascular system make it an appealing target for future
studies that isolate its downstream targets in the heart.
In addition to proteins involved in differentiation and adhesion/
migration, several proteins involved in the IGF/insulin pathway
were identified in our study. Early in embryogenesis the embryo
does not produce insulin nor does maternal insulin cross the
placental barrier. However, embryos express high levels of IGF
receptors and early growth is mediated via IGF signaling through
Akt. Factors that regulate IGF receptor engagement and its
downstream signaling cascades were identified both on the
extracellular face, including the proteases Pcsk1 and ST14, and
the intracellular face, including ZFP106 (or son of insulin receptor
mutant) and HES6. Pcsk1 is a secreted protease that cleaves
precursors including neuropeptides, renin, somatostatin, and
insulin/IGF [71]. Additionally substrates include adhesion mole-
cules,proteasesandreceptors.Pcsk1KOmiceareviable,butgrowth
retarded. Two strains of proprotein convertase KO mice, Furin and
PACE4, exhibit defects in the vasculature and heart, while the other
8 proprotein convertase KO mice exhibit defects in hormone
production, fertility, and lipid metabolism [71]. Our data demon-
strating decreased Pcsk1 levels in the yolk sac after hyperglycemia
insult suggests that Pcsk1 KO mice may have an unappreciated
inducible vascular phenotype. We also demonstrated that Pcsk1 is
predictive for CHDs, expressed in the embryonic myocardium, and
increased in the AF of fetuses with CHDs. Pcsk1 downregulation in
the yolk sac and upregulation in AF may reflect differences in
developmental age, cell differentiation processes or clearance/
accumulation of proteins in the AF versus tissue. Although
proprotein convertases have been linked to Alzheimer’s disease,
tumorigenesis, and infections, they have not been previously
reported to have a role in CHDs. Further given that gene knock
out experimentshavedetermined that individual PCs do not seemto
be redundant in embryonic development, understanding the role of
Pcsk1 in metabolism, growth, and development of cardiovascular
system is an intriguing avenue of future investigation.
Another molecule in the IGF signaling pathway, ST14, a
transmembrane serine protease, has been implicated in metastatic
cancer, which utilizes a molecular program reminiscent of
embryonic EMT [72]. Substrates for ST14 include hepatocyte
growth factor, urokinase-type plasminogen activator, protease-
activated receptor 2 (PAR-2), IGF binding protein-related protein-
1, trask, laminin and fibronectin [73,74]. Recently, VEGFR-2 was
reported to be a putative substrate of ST14 in HUVECs, resulting
in ectodomain cleavage and inactivation of cell signaling [75].
Here, we demonstrated for the first time that ST14 is present in
the embryonic cardiovascular system and is predictive of CHDs.
Given the known substrates of this protease, ST14 induction
during vasculopathy and in AF of fetuses with CHDs may affect
differentiation, adhesion/migration and growth.
Cell movements, growth and differentiation depend on environ-
mentalhomeostasis;ofparticular importanceduringdevelopmentis
redox balance. According to current knowledge, SVCT transports
ascorbate into cells and thereby participates in metabolic processes,
matrix synthesis and antioxidant defense [76]. Interestingly,
dehydroascorbate utilizes glucose transporters to enter the cell
prior to conversion to ascorbate, and during a hyperglycemic
episode glucose competitively inhibits the transport of dehydroas-
corbate, potentially compromising antioxidant defense and leading
to reactive oxygen species induced damage [77,78]. Consistent with
the theory of ROS induced vasculopathy; our data demonstrating
upregulation of SVCT may signify that the embryo is ‘‘at risk’’ and
employing a defense to combat oxidative stress. Although SVCT
was not predictive of CHDs, the fetal cardiovascular system is
sensitive to oxidative stress and benefits from antioxidant supple-
ments, such as folic acid [13,79,80]. Therefore understanding the
upstream regulation, downstream targets, and/or activity of SVCT
may shed light onto novel antioxidant therapies for fetuses ‘‘at risk’’.
Molecular-based diagnostic tests that detect fetuses ‘‘at risk’’
provide clinicians with information to guide clinical interventions
aimed at improving outcome. First-trimester biochemical screening is
becoming a powerful tool, allowing clinicians to efficiently triage
patients [81]. For example, increased pregnancy-associated plasma
protein A (PAPP-A) and decreased free b-human chorionic
gonatrophin (b-hCG) in maternal serum indicate increased risk of
trisomy 21, while reduced PAPP-A in maternal serum is associated
with an increased risk of trisomy 18 [81]. An obvious advantage of
serum screening is that it is non-invasive and serum screening may be
performed earlier than amniocentesis. In the present study, we
utilized AF rather than maternal serum because of its low complexity
and similarity to the fetus due to its origin. Cells in AF are fetal rather
than maternal. Future studies involving early maternal serum samples
are required to determine the merit of adding our biomarkers to
existing screening panels. To this end, using an in vivo streptozocin-
induced diabetic model in mice, we detected differences in specific
Laminin chains, ADAM15 ectodomain, and MMP2 activity in
maternal sera from mice carrying a high proportion of fetuses with
heartdefectscompared tothosewithahighproportionoffetuseswith
normal hearts (unpublished data). These data suggest that protein
fragments are released into the maternal circulation in sufficient
quantities that allow detection early in pregnancy (E10.5 which is
approximately equivalent to human developmental week 6).
Experiments are currently underway to evaluate the levels of
WNT16, ST14, and Pcsk1 in maternal sera from murine models
and humans.
The creation ofnewbiochemicaldiagnostictoolstoassayproteins
such as Pcsk1, ST14, and WNT16 may give insights into the well-
being of the fetus by sensing an inability to combatan environmental
insult, disruption in growth, or damage due to reactive oxygen
species.Affordable,rapid,andaccuratemolecular-based diagnosisof
potential problems in fetal cardiovascular development early in
pregnancy will provide clinicians with information to guide clinical
interventions and pave the way toward eradicating one of the major
global causes of infant mortality in the world. In the future, dietary
supplementation or molecular therapies based on Pcsk1, ST14 and
WNT16 or their targets may ameliorate the deficiencies that
ultimately lead to the formation of a CHD in the first trimester.
Therefore isolating the specific substrate targets of ST14 and Pcsk1
that disrupt cardiac development and investigating the transcrip-
tional or post-transcriptional regulatory mechanisms that lead to
overexpression of ST14 and Pcsk1 will aid in deciphering the role of
these proteins in the etiology of CHDs. Further, continued mining of
the proteomic dataset coupled with analysis of novel factors in
physiologically relevant models will continue to yield fruitful avenues
for investigation into the biology of cardiovascular development and
pathogenic mechanisms of CHDs in the hope of advancing
prevention, diagnosis and treatment.
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